E-viri
Recenzirano
-
Casadei‐Gardini, Andrea; Scartozzi, Mario; Tada, Toshifumi; Yoo, Changhoon; Shimose, Shigeo; Masi, Gianluca; Lonardi, Sara; Frassineti, Luca Giovanni; Nicola, Silvestris; Piscaglia, Fabio; Kumada, Takashi; Kim, Hyung‐Don; Koga, Hironori; Vivaldi, Caterina; Soldà, Caterina; Hiraoka, Atsushi; Bang, Yeonghak; Atsukawa, Masanori; Torimura, Takuji; Tsuj, Kunihiko; Itobayashi, Ei; Toyoda, Hidenori; Fukunishi, Shinya; Rimassa, Lorenza; Rimini, Margherita; Cascinu, Stefano; Cucchetti, Alessandro; Nakamura, Shinichiro; Michitaka, Kojiro; Itokawa, Norio; Hayama, Korenobu; Hirooka, Masashi; Koizumi, Yohei; Hiasa, Yoichi; Ishikawa, Toru; Imai, Michitaka; Takaguchi, Koichi; Tsutsui, Akemi; Nagano, Takuya; Kariyama, Kazuya; Nouso, Kazuhiro; Tajiri, Kazuto; Shimada, Noritomo; Shibata, Hiroshi; Ochi, Hironori; Joko, Kouji; Yasuda, Satoshi; Ohama, Hideko; Kawata, Kazuhito
Liver international, June 2021, Letnik: 41, Številka: 6Journal Article
Purpose Data from common clinical practice were used to generate balanced cohorts of patients receiving either sorafenib or lenvatinib, for unresectable hepatocellular carcinoma, with the final aim to investigate their declared equivalence. Methods Clinical features of lenvatinib and sorafenib patients were balanced through inverse probability of treatment weighting (IPTW) methodology, which weights patients’ characteristics and measured outcomes of each patient in both treatment arms. Overall survival was the primary endpoint and occurrence of adverse events was the secondary. Results The analysis included 385 patients who received lenvatinib, and 555 patients who received sorafenib. In the unadjusted cohort, lenvatinib did not show a survival advantage over sorafenib (HR: 0.85, 95% CI 0.70‐1.02). After IPTW adjustment, lenvatinib still not returned a survival advantage over sorafenib (HR: 0.82, 95% CI: 0.62‐1.07) even in presence of balanced baseline characteristics. Lenvatinib provided longer survival than sorafenib in patients previously submitted to TACE (HR: 0.69), with PS of 0 (HR: 0.73) or without extrahepatic disease (HR: 0.69). Conclusion Present results confirmed randomized controlled trial in the real‐life setting, but also suggests that in earlier stages some benefit can be expected.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.